On November 19, Swiss pharmaceutical giant Novartis AG (NVS) released its latest medium- to long-term performance outlook, projecting that sales will maintain an average annual growth rate of 5% through 2031 at constant exchange rates, with the core operating margin expected to recover to 40% or above by 2029.
Although the heart failure treatment Entresto faces generic competition, putting pressure on the company's profitability, Novartis AG (NVS) CEO Vas Narasimhan said the company is expected to continue achieving business growth while navigating the largest wave of drug patent expirations in its history in 2026.
Raises Sales Forecasts for Three Core Drugs
Novartis AG (NVS) raised its peak annual sales forecasts for three drugs: Kesimpta, from $6 billion to $8 billion; Scemblix, from $4 billion to $5 billion; and Leqvio, from $4 billion to $5 billion.
Previously, Novartis AG (NVS) had also raised its peak annual sales forecast for Rhapsido (Remibrutinib) to $8 billion, covering indications such as chronic spontaneous urticaria, chronic inducible urticaria, and relapsing multiple sclerosis.
Currently, Novartis AG (NVS) has nine marketed drugs or product lines with peak annual sales potential of $3 billion to $10 billion, namely Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma series (including Zolgensma and Itvisma), and Fabhalta.
Rich R&D Pipeline Supports Long-Term Growth
Novartis AG (NVS) expects to announce more than 35 clinical trial results by 2031 that could support regulatory approval applications.
Currently, the company's R&D pipeline contains more than 30 candidate drugs with high commercial value potential, of which more than 20 are in registration, Phase II, or Phase III clinical trials, and more than 10 are in or about to enter Phase I clinical trials.
In addition, 10 drugs in late-stage development are expected to achieve peak annual sales in the billions of dollars.
Key investigational drugs that Novartis AG (NVS) is focusing on include Abelacimab for preventing stroke in patients with atrial fibrillation, QCZ484 for treating hypertension, Pelabresib for treating myelofibrosis, and 225Ac-PSMA-617 for treating prostate cancer.
Novartis AG (NVS) believes that its existing marketed drugs and R&D pipeline together will support the company in achieving mid-single-digit sales growth over the long term.
Comments